For growth equity investing, Q4 projections in edtech point to strong adoption rates in emerging markets, where digital learning platforms expect >25% annual revenue growth backed by mobile penetration increases. All in all, I'd say Vita Coco has a good shot of multibagger returns over the long term, even if its current price-to-earnings (P/E) ratio of around 40 looks pricey at the moment. As such, it's a name to watch, especially for younger investors, and a stock to pick up on any pullbacks. Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events. Growth equity investing trends in biotech indicate accelerated funding activity following several FDA approvals, with valuations climbing 12% over the past six months and investor focus shifting to commercial scalability.